CHMP recommends licence extension for HyQvia brand human normal immunoglobulin

The licensed extension for this brand of immunoglobulin is for use in secondary immunodeficiencies in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure or serum IgG level of <4 g/l.


European Medicines Agency